ArticleBMC pulmonary medicine2025
Clinical utility of lung diffusing capacity for carbon monoxide (DLco) in children: a retrospective single-center study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma KL-6 reflects pulmonary severity and longitudinal response to enzyme replacement therapy in acid sphingomyelinase deficiency type B.Molecular genetics and metabolism reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffusing capacity for carbon monoxide (DLco) testing is widely used in adult respiratory medicine, but its role in pediatric care remains unclear. This study aimed to assess the diagnostic and clinical utility of DLco testing in children at a single tertiary center.
methodsWe conducted a retrospective analysis of DLco and spirometry data from all children who underwent pulmonary function testing at the University Children's Hospital Zurich between 2015 and 2025. Tests meeting ATS/ERS quality criteria (Grades A/B) and performed alongside same-day blood counts were included. Patients were categorized as undergoing initial diagnostic evaluation or follow-up monitoring.
resultsOut of 269 DLco tests from 202 patients (median age 13.4 years), 72 tests (26.7%) were excluded due to insufficient quality. The final cohort included 197 tests from 144 patients. Among 54 children undergoing DLco as part of initial assessment, none had abnormal values or changes in diagnosis or management. In the follow-up group (n = 90), 16 patients (8.1%) had DLco z-scores below the lower limit of normal, but these findings did not influence clinical decisions. No significant correlation was observed between DLco and FEV1 z-scores (p = 0.399). Longitudinal data from 31 patients showed no significant changes in DLco.
conclusionsDLco testing in children is technically challenging, with a high proportion of tests failing quality standards. Abnormal results were rare and did not impact clinical management. These findings suggest limited routine utility for DLco in pediatric populations, underscoring the need for targeted indications and further prospective research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.